Sphenopalatine Ganglion Stimulation in the Pathway CH-1 Study Reduces Headache Burden Before and After Sustained Periods of Cluster Attack Remission
Budapest, Hungary - During the world congress of controversies in Neurology, CONy, Autonomic TechnologiesTM presented long term data* (18 months results) on a segment of the CH-1 study patients experiencing Cluster Headache Remission periods. While Sphenopalatine Ganglion (SPG) stimulation with the PulsanteTM microstimulator has already shown safety and efficacy on chronic cluster headache, long-term benefits of SPG stimulation in cluster patients with remission suggest that the therapy is beneficial during the episodic phase of patients' cluster bouts.
"This data strongly suggest that SPG stimulation could be beneficial also to episodic cluster patients", commented Prof. Miguel Láinez, Head of Neurology Department at Catholic University of Valencia and Professor of Neurology in the Catholic University of Valencia who presented the data on March 28th.
Pulsante microstimulator is the first electroceutical device that has documented efficacy in a long term RCT for the treatment of cluster headache. The Pulsante microstimulator is MR Conditional since 2012. The device is inserted through the gum with a minimally invasive technique that leaves no visible scars.
Autonomic Technologies, Inc. (ATITM) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company's initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.
ATI is headquartered in the San Francisco Bay Area and is backed by blue chip investors: Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic. www.pulsante.eu
*Poster Presentation at 9th CONy Congress, Budapest, March 28th 2015